Phuturdex › Drugs › Entrectinib
Drugs in development · updated 30 October 2026
Entrectinib: clinical trials and development status
Other names and codes: Rozlytrek
As of 30 October 2026 Entrectinib is in 17 active clinical trials (recruiting or ongoing, phases I–III) for 27 diseases. The most advanced phase is III.
Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Entrectinib and get an email at every change or safety alert.
Sign in free →Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Non-small-cell lung carcinoma | III | 5 | NCT04603807 |
| Brain Neoplasms | II–III | 4 | NCT05770544 |
| Neoplasm | III | 4 | NCT05862285 |
| Glioma | II–III | 3 | NCT05770544 |
| Hematologic neoplasm | II–III | 3 | NCT05722886 |
| Lymphoproliferative disorders | II–III | 2 | NCT05722886 |
| Melanoma | II–III | 2 | NCT05770544 |
| Central nervous system neoplasm | II | 2 | NCT06528691 |
| Metastasis | II | 2 | NCT03994796 |
| Papillary thyroid cancer | II | 2 | NCT02568267 |
| Salivary gland neoplasm | II | 2 | NCT02568267 |
| Sarcoma | II | 2 | NCT02568267 |
| Anaplastic large-cell lymphoma | II | 1 | NCT02568267 |
| Breast neoplasm | II | 1 | NCT02568267 |
| Cholangiocarcinoma | II | 1 | NCT02568267 |
| Colorectal neoplasm | II | 1 | NCT02568267 |
| Ewing sarcoma | I–II | 1 | NCT02650401 |
| Head and neck neoplasms | II | 1 | NCT02568267 |
| Medulloblastoma | I–II | 1 | NCT02650401 |
| Mesoblastic nephroma | I–II | 1 | NCT02650401 |
| Neuroblastoma | I–II | 1 | NCT02650401 |
| Neuroendocrine tumor | II | 1 | NCT02568267 |
| Ovarian neoplasm | II | 1 | NCT02568267 |
| Pancreatic neoplasm | II | 1 | NCT02568267 |
| Renal cell carcinoma | II | 1 | NCT02568267 |
| Wilms Tumor | I–II | 1 | NCT02650401 |
| Acute myeloid leukemia | I | 1 | NCT05396859 |
Everything on Entrectinib
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.